Navigation Links
OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial
Date:3/14/2012

excellence with key opinion leaders in melanoma clinical research for its metastatic melanoma phase II study.

About OncoSec's Metastatic Melanoma Phase II Study (OMS-I100)

A total of up to 25 patients with stage III or IV cutaneous and in-transit metastatic melanoma will be enrolled in this Phase II, single-arm, open-label and multi-center study. The trial is designed to assess local and distant objective response following treatment of cutaneous melanoma lesions with DNA IL-12 and electroporation with a primary endpoint of 24 weeks. One treatment cycle will consist of three treatments applied to up to four lesions on days 1, 5 and 8 with a maximum dose of 1.5 mg DNA IL-12 per treatment cycle. At 12 months, patients will be moved to the follow-up phase of the study and will be followed for up to five years for safety.

OMS ElectroImmunotherapy utilizes OncoSec's proprietary technology to deliver a DNA-based cytokine coded for the immune stimulating agent interleukin-12, or DNA IL-12. The OncoSec Medical System (OMS) applies short electric impulses to the tumor, causing pores to open in the membrane of cancer cells that significantly increases DNA IL-12 uptake into these cells. Phase I data using OMS ElectroImmunotherapy to treat malignant melanoma demonstrated that this therapy was safe and well tolerated. In addition, 53% of patients with distant metastatic lesions demonstrated an objective response, with 15% of these patients having a complete response to the treatment.

About Melanoma

Melanoma is the most serious form of skin cancer. If it is recognized and treated early, it is almost always curable, but if it is not, the cancer can advance and spread to other parts of the body, where it becomes hard to treat and can be fatal. While it is not the most common of the skin cancers, it causes the most deaths. The American Cancer Society estimates that at present, about 123,000 new cases of melanoma in the US are diagnos
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. OncoSec to Evaluate Potential Predictive or Prognostic Biomarkers for Treatment of Solid Tumor Cancers Using OMS ElectroImmunotherapy
2. OncoSecs OMS ElectroImmunotherapy Technology Platform and its Ongoing Phase II Merkel Cell Carcinoma Clinical Trial Featured in Seattle Newspaper
3. OncoSec Doses First Patient in Phase II Clinical Trial for Metastatic Melanoma
4. OncoSec to Present at World Cancer Immunotherapy Conference
5. OncoSec to Present at the 22nd Annual Oppenheimer Healthcare Conference
6. OncoSec to Present at 15th Annual Biotech and Specialty Pharmaceuticals Conference
7. OncoSec and Serametrix Collaborate to Identify Potential Biomarkers to Enhance Skin Cancer Immune Therapies
8. OncoSec to Present at Medical Device Investor Forum
9. Device Master File for OncoSec Medical System Completed and Submitted to FDA
10. OncoSec Releases Devices for Use in Clinical Trials
11. Update: OncoSec Announces Positive Results From Head & Neck and Breast Cancer Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... YORK and PLAINSBORO, N.J. ... announced today its support of the National Hemophilia ... Care , which provides support to people with ... physical and psychosocial challenges that can impede disease ... six modules, Communication With Your Provider About ...
(Date:9/18/2014)... 18, 2014 After 6 months of ... finally here - the new programme for the next Cool ... of our global Cool Chain series, has just been released! ... As the lines between supply chain, logistics, QA ... programme that is broad and yet specific, focused and yet ...
(Date:9/18/2014)... 18, 2014   Regulus Therapeutics Inc . ... leading the discovery and development of innovative medicines ... ATHENA natural history of disease study in patients ... with no approved therapy. The ATHENA study is ... function markers such as Glomerular Filtration Rate ("GFR"), ...
Breaking Medicine Technology:Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 2Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 3Europe's Biggest and Longest-Running Gathering of Life Sciences Logistics, Supply Chain & QA Professionals 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 2Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 3Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 4Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 5Regulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients 6
... March 31, 2011 Watson Pharmaceuticals, Inc. (NYSE: ... is initiating launch activities of Nulecit™ (sodium ferric ... of GeneraMedix Inc.,s, Abbreviated New Drug Application (ANDA). ... alternative to Sanofi-Aventis, Ferrlecit ® .  In July ...
... DIEGO, March 31, 2011 OncoSec Medical Inc. (OTC BB: ... tumor cancers, announced today that it has raised more than ... to three institutional investors. OncoSec issued 1,456,000 units at a ... Each unit consisted of one share of common stock and ...
Cached Medicine Technology:Watson Announces Approval of Nulecit™, the First Generic Alternative to Ferrlecit® for the Treatment of Iron Deficiency Anemia 2Watson Announces Approval of Nulecit™, the First Generic Alternative to Ferrlecit® for the Treatment of Iron Deficiency Anemia 3Watson Announces Approval of Nulecit™, the First Generic Alternative to Ferrlecit® for the Treatment of Iron Deficiency Anemia 4OncoSec Medical Closes $1.1M Financing 2
(Date:9/18/2014)... Springs, FL (PRWEB) September 18, 2014 It ... and run, sprint or walk for healthier and happier kids. ... support and participate in the 4th Annual Miami Children’s Hospital ... Wheels. http://www.hyundaihopeonwheels.org , The 5K will ... finishing location will be outside of Coral Gables City Hall ...
(Date:9/18/2014)... Johannesburg, South Africa (PRWEB) September 18, 2014 ... organization to adopt the HABIT™ Program in ... by Indaba Health and Wellness, and distributed in South ... version of the HABIT program, which has been tailored ... , IHW HABIT™ focuses on behavior modification and chronic ...
(Date:9/18/2014)... . Two ... ,International Space Station Research Competition, with their project ,Egypt ... will see the International Space Station crew perform experiments ... proteins of the hepatitis C virus under microgravity conditions. ... Station is scheduled to lift off from Cape Canaveral ...
(Date:9/18/2014)... 18, 2014 PlatinumCode, a leading ... collection products for the healthcare industry, announced earlier ... five percent of their profits of the sale ... In making the announcement, PlatinumCode has launched various ... providing clinical and hospital labs with their popular ...
(Date:9/18/2014)... 2014 T-System Inc. today announced ... documentation system — EV™ for physicians ... assessing several best-of-breed solutions, Holyoke chose T-System’s solution ... physician productivity and reimbursement, but also its ability ... still be used to capture emergency department, (ED) ...
Breaking Medicine News(10 mins):Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 2Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 3Health News:Hepatitis C virus proteins in space 2Health News:PlatinumCode Commits to Donating Five Percent of Profits from the sale of Pink Products to Support Breast Cancer Awareness 2Health News:Holyoke Medical Center ER Improves Productivity and Reimbursement with T-System 2
... active participation in their communities has led researchers to define this ... now be considered a distinct retirement role, according to an article ... (Volume 48, Number 3). , The authors identify civic ... one day per week that directly impact the local community. ...
... 6 hours for participants in phase II trial ... gout drug called pegloticase lowered levels of uric acid ... hours in most patients. , That,s the conclusion of ... and Savient Pharmaceuticals, the company that,s developing the drug. ...
... Ill., Sept. 3 Z Trim Holdings,Inc. (Amex: ... 2, 2008, the Company,entered into private placement subscription ... of convertible notes and warrants, for an,aggregate offering ... a,"Unit" and collectively, the "Units") consists of a ...
... 28,000 ratings and comments are overwhelmingly positive, ... of,Regence members would recommend their doctor to others, ... member Web site -- myRegence.com. A,"Member Feedback" feature ... on their experiences with individual providers, including,physicians, dentists, ...
... (doi:10.1016/j.clim.2008.06.009) published in Clinical Immunology, the official ... new method enabling the detection of multiple parameters of ... specific blood cells from an individual with type 1 ... play in the development of the disease and during ...
... on earnings and productivity for healthcare professionals in the United States, ... decrease in patient loads. , ... New York, NY ... focusing on earnings and productivity for physicians in America features some ...
Cached Medicine News:Health News:Experts establish baseline for civic engagement among retirees 2Health News:New Drug Helps Relieve Gout 2Health News:Z Trim Holdings, Inc. Announces Private Placement Funding 2Health News:Z Trim Holdings, Inc. Announces Private Placement Funding 3Health News:Doctors Get High Marks as Regence Members Share Opinions Online 2Health News:Fresh Medical Industry News Reveals Earnings & Productivity Changes For Physicians 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: